dapagliflozin

Details

Generic Name:

dapagliflozin

Project Status:

Not filed

Therapeutic Area:

Chronic kidney disease

Manufacturer:

AstraZeneca Canada Inc.

Brand Name:

Forxiga

Project Line:

Reimbursement Review

Project Number:

N/A

Submission Type:

Non Submission

Indications:

To reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular and renal death in adults with chronic kidney disease (CKD).

Recommendation Type:

CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer

Last Updated : November 1, 2021